Flex Pharma (FLKS) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Flex Pharma Reports First Quarter 2018 Financial Results
May 2, 2018 7:00 AM EDT
-- Positive Anti-Cramping Effect of FLX-787 Reported in Recent MS
study --
-- FLX-787 Phase 2 ALS & CMT Clinical Studies
Ongoing --
Conference Call Scheduled Today at 9:00 a.m. ET
BOSTON--(BUSINESS WIRE)-- Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for muscle... More
